EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 156 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $39,949 | -31.5% | 2,055 | 0.0% | 0.00% | – |
| Q1 2023 | $58,300 | -21.0% | 2,055 | -18.6% | 0.00% | – |
| Q4 2022 | $73,777 | +6.9% | 2,524 | -3.8% | 0.00% | – |
| Q3 2022 | $69,000 | -41.0% | 2,623 | 0.0% | 0.00% | -100.0% |
| Q2 2022 | $117,000 | -11.4% | 2,623 | -1.6% | 0.00% | 0.0% |
| Q1 2022 | $132,000 | +25.7% | 2,665 | +29.7% | 0.00% | 0.0% |
| Q4 2021 | $105,000 | -8.7% | 2,055 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $115,000 | +30.7% | 2,055 | 0.0% | 0.00% | – |
| Q2 2021 | $88,000 | +2.3% | 2,055 | 0.0% | 0.00% | -100.0% |
| Q1 2021 | $86,000 | -10.4% | 2,055 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $96,000 | +10.3% | 2,055 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $87,000 | -12.1% | 2,055 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $99,000 | +125.0% | 2,055 | +114.1% | 0.00% | – |
| Q1 2020 | $44,000 | -24.1% | 960 | 0.0% | 0.00% | – |
| Q4 2019 | $58,000 | +7.4% | 960 | 0.0% | 0.00% | – |
| Q3 2019 | $54,000 | +1.9% | 960 | 0.0% | 0.00% | – |
| Q2 2019 | $53,000 | +10.4% | 960 | 0.0% | 0.00% | – |
| Q1 2019 | $48,000 | +23.1% | 960 | 0.0% | 0.00% | – |
| Q4 2018 | $39,000 | -41.8% | 960 | 0.0% | 0.00% | -100.0% |
| Q3 2018 | $67,000 | -8.2% | 960 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $73,000 | +204.2% | 960 | +112.9% | 0.00% | – |
| Q1 2018 | $24,000 | 0.0% | 451 | 0.0% | 0.00% | – |
| Q4 2017 | $24,000 | -11.1% | 451 | 0.0% | 0.00% | – |
| Q3 2017 | $27,000 | -25.0% | 451 | 0.0% | 0.00% | – |
| Q2 2017 | $36,000 | -2.7% | 451 | 0.0% | 0.00% | – |
| Q1 2017 | $37,000 | +2.8% | 451 | 0.0% | 0.00% | – |
| Q4 2016 | $36,000 | +33.3% | 451 | +16.8% | 0.00% | – |
| Q3 2016 | $27,000 | +80.0% | 386 | 0.0% | 0.00% | – |
| Q2 2016 | $15,000 | -6.2% | 386 | 0.0% | 0.00% | – |
| Q1 2016 | $16,000 | -52.9% | 386 | 0.0% | 0.00% | – |
| Q4 2015 | $34,000 | +385.7% | 386 | +315.1% | 0.00% | – |
| Q3 2015 | $7,000 | – | 93 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |